Cargando…

The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy

PURPOSE OF REVIEW: To summarize the targeted therapies and immunotherapy of Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant non-small cell lung cancer (NSCLC), and discuss the ongoing clinical trials. RECENT FINDINGS: KRAS mutations occur in about 30% of patients with NSCLC and are the seco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shu, Chun-Lu, Liu, Yu-Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767706/ https://www.ncbi.nlm.nih.gov/pubmed/36561983 http://dx.doi.org/10.2147/CMAR.S387665

Ejemplares similares

Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival
por: Amanam, Idoroenyi, et al.
Publicado: (2020)

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
por: Shen, Mo, et al.
Publicado: (2022)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
por: Uras, Iris Z., et al.
Publicado: (2020)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
por: Zeitouni, Daniel, et al.
Publicado: (2016)

Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
por: Maroni, Giorgia, et al.
Publicado: (2021)

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
por: Désage, Anne-Laure, et al.
Publicado: (2022)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Current therapy of KRAS-mutant lung cancer
por: Ghimessy, Aron, et al.
Publicado: (2020)

Targeting KRAS in Non-Small Cell Lung Cancer
por: Corral de la Fuente, Elena, et al.
Publicado: (2022)

Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer
por: Shaurova, Tatiana, et al.
Publicado: (2020)

Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review
por: Santarpia, Mariacarmela, et al.
Publicado: (2023)

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
por: Brunelli, Laura, et al.
Publicado: (2014)

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
por: Xie, Mingying, et al.
Publicado: (2021)

Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
por: Li, Yunchang, et al.
Publicado: (2022)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
por: Adderley, Helen, et al.
Publicado: (2019)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
por: Sunaga, Noriaki, et al.
Publicado: (2021)

Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer
por: Yu, Xiangjing, et al.
Publicado: (2021)

Targeting KRAS mutant lung cancer: light at the end of the tunnel
por: Drosten, Matthias, et al.
Publicado: (2022)

SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer
por: Wang, Xiaowen, et al.
Publicado: (2021)

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
por: Ceddia, Serena, et al.
Publicado: (2022)

Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
por: Wang, Yadong, et al.
Publicado: (2022)

Targeted therapies and immunotherapy in non-small-cell lung cancer
por: Cortinovis, D, et al.
Publicado: (2016)

Small molecular inhibitors for KRAS-mutant cancers
por: Wu, Xuan, et al.
Publicado: (2023)

Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China
por: Gu, Guomin, et al.
Publicado: (2022)

Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells
por: Chen, J, et al.
Publicado: (2013)

DRP1 promotes lactate utilization in KRAS‐mutant non‐small‐cell lung cancer cells
por: Hu, Mangze, et al.
Publicado: (2020)

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
por: Araujo, Luiz Henrique, et al.
Publicado: (2021)

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy
por: Almotlak, Abdulaziz A., et al.
Publicado: (2021)

Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer
por: Roh, Jae-il, et al.
Publicado: (2020)

Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer
por: Chao, Yi-Chun, et al.
Publicado: (2021)

Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer
por: Sa, Huanlan, et al.
Publicado: (2019)

Immunotherapy as a targeted therapy in non-small cell lung cancer
por: Rocco, Danilo, et al.
Publicado: (2019)

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
por: Zhu, Chunxiao, et al.
Publicado: (2022)

Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer
por: Tan, Daniel SW, et al.
Publicado: (2014)

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
por: Zheng, Yawen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vn42eblg449h0j8sul80fqko80